AG
CBIO

Artal Group’s Crescent Biopharma CBIO Stock Holding History

Artal Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-85,891
Closed -$2.42M – 39
2024
Q2 		$2.42M Hold
85,891
– – 0.06% 74
2024
Q1 		$25.8M Hold
85,891
– – 0.66% 21
2023
Q4 		$20.3M Hold
85,891
– – 0.69% 21
2023
Q3 		$12.9M Hold
85,891
– – 0.56% 28
2023
Q2 		$14.9M Hold
85,891
– – 0.48% 32
2023
Q1 		$10.8M Buy
+85,891
New +$19.3M 0.64% 39
2018
Q3 		– Sell
-2,500
Closed -$4.03M – 120
2018
Q2 		$4.03M Sell
2,500
-750
-23% -$1.29M 0.11% 74
2018
Q1 		$5.28M Buy
3,250
+750
+30% +$1.56M 0.08% 65
2017
Q4 		$4.2M Buy
2,500
+475
+23% +$628K 0.08% 76
2017
Q3 		$2.83M Hold
2,025
– – 0.06% 83
2017
Q2 		$2.26M Buy
+2,025
New +$1.67M 0.05% 94

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return